<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        59-887-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LANOXIN 0.125MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIGOXIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN Bad Oldesloe GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN Bad Oldesloe GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;What Lanoxin is and what it is used for</strong></p><p>Lanoxin Tablets contains the active substance digoxin, which belongs to a group of medicines called cardiac glycosides. It is used to treat arrhythmias and heart failure. An arrhythmia is an irregularity in the heart-beat, which causes the heart to skip a beat, beat irregularly or beat at the wrong speed. This medicine works by correcting irregular heartbeats to a normal rhythm and strengthens the force of the heart-beat, which is why it is useful in heart failure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp; &nbsp;What you need to know before you use Lanoxin Tablets </strong></p><p><strong>Do not use Lanoxin Tablets if you:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Are allergic to digoxin, other cardiac glycosides or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have serious heart problems, such as those with the conduction of the electrical impulses in the heart, especially if you have a history of Stokes-Adams attacks (abrupt, short-lived loss of consciousness caused by a sudden change in heart rate or rhythm).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have an irregular heart-beat caused by cardiac glycoside intoxication or conditions such as Wolff-Parkinson-White syndrome.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have obstructive cardiomyopathy (enlargement of the heart muscle).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before using this medicine:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking this medicine, your doctor may ask you to have regular blood tests to determine the amount of Lanoxin in the blood. This may be useful in the case of patients with kidney disorders.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop digoxin toxicity, this can lead to various forms of heart rhythm disturbances, some of which resemble the rhythm disturbances for which the product was prescribed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have abnormal heart rhythm (heart block) and you are taking this medicine, contact your doctor immediately if you feel one or more of the following symptoms: fainting, short-lasting loss of consciousness, dizziness or light-headedness, fatigue (tiredness), shortness of breath, chest pain, irregular heart-beat or confusion.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a sinoatrial disorder (a disorder in the conduction of electrical impulses in the heart such as Sick Sinus Syndrome), in some patients with a sinoatrial disorder this medicine can cause a slow and/or irregular heart-beat. Sometimes this will cause tiredness, weakness and dizziness and when your heartbeat is very slow you may faint.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recently suffered a heart attack.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When heart failure occurs along with the collection of an abnormal protein in the heart tissue (cardiac amyloidosis), an alternative therapy may be prescribed by the doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have myocarditis (inflammation of the heart muscle) this may cause vasoconstriction (narrowing of the blood vessels) on rare occasions. Your doctor may prescribe you a different medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have Beri-beri disease (caused by a vitamin B1 deficiency).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have constrictive pericarditis (inflammation of the sac which contains the heart).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking diuretics (drugs which promote urine production and help reduce the amount of water in your body) with or without an ACE inhibitor (mainly used to treat high blood pressure), your doctor will prescribe a lower dose of Lanoxin. Do not stop taking Lanoxin without talking to your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a heart test called an ECG (electrocardiogram), tell the person doing the test that you are taking Lanoxin as it can affect the meaning of the results.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe respiratory (lung) disease (as you may have an increased sensitivity to Lanoxin).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have low levels of oxygen reaching certain parts of your body, low levels of potassium, abnormally low levels of magnesium or increased levels of calcium in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have thyroid disease (such as an under-active or over-active thyroid) as you might require changes in the dose of this medicine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have malabsorption syndrome (you cannot absorb minerals from your food properly) or if you have ever had gastrointestinal reconstruction surgery.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you will receive electric shock treatment to correct an abnormal heart-beat.</p><p><strong>Other medicines and Lanoxin Tablets</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Taking several medicines can sometimes have harmful consequences or lead to unwanted interactions.</p><p><u>Sensitivity to Lanoxin can be increased by</u> medicines which lower the level of potassium in the blood. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diuretics,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium salts (antidepressants),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroid based products,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbenoxolone (a product which strengthens the gastric mucosa).</p><p>The following medicines <u>increase the level of Lanoxin</u> in the blood, which can increase the risk of toxicity:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain products which affect the heart: amiodarone, flecainide, prazosin, propafenone, quinidine, Captopril,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; canagliflozin (used to treat of type 2 diabetes mellitus),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain&nbsp;&nbsp;&nbsp; antibiotics:&nbsp;&nbsp;erythromycin,&nbsp;&nbsp;clarithromycin, tetracycline,&nbsp;&nbsp;gentamicin, trimethoprim,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; daclatasvir (used in combination with other medications to treat hepatitis C),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flibanserin (used to treat low sexual desire in women who have not gone through menopause),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; isavuconazole (used to treat fungal infections),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole (used to treat fungal infections),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ivacaftor (used to treat cystic fibrosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spironolactone (a drug which increases the amount of urine you produce),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alprazolam (a sedative which may be used to treat anxiety),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indomethacin (used to treat inflammation),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; quinine (may be used to prevent malaria infection),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; propantheline (used to prevent muscle spasms),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mirabegron (used to treat overactive bladder that causes a sudden urge to urinate resulting in involuntary loss of urine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nefazodone (an antidepressant),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atorvastatin (lowers blood cholesterol),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine (an immunosuppressant often used to prevent transplant rejection),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epoprostenol (used to treat pulmonary arterial hypertension),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolvaptan (used to treat low blood sodium levels),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conivaptan (used to treat low blood sodium levels),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carvedilol (used to treat mild to severe congestive heart&nbsp; failure and high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir &amp; saquinavir (used to treat HIV infection and AIDS),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Telaprevir (used to treat hepatitis C infection),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone (used to treat irregular heart-beat),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ranolazine (used to treat chest pain),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simeprevir (used in combination with other medications to treat hepatitis C),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; telmisartan (used to treat high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lapatinib (used to treat breast cancer),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ticagrelor (used to prevent heart attack or stroke),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil (used to treat high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; felodipine (used to treat high blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiapamil (used to treat chest pain),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vandetanib (used to treat certain cancers of the thyroid gland),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; velpatasvir (used in combination with other medications to treat hepatitis C),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-glycoprotein inhibitors.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Venetoclax (is used to treat patients with chronic lymphocytic leukaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vemurafenib (used to treat adult patients with a type of cancer called melanoma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proton pump inhibitors (PPIs) such as Rabeprazole (used to relieve symptoms of acid reflux, or gastroesophageal reflux disease (GERD)</p><p>The following medicines may <u>increase or have no effect on the levels of Lanoxin</u> in the blood:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nifedipine, diltiazem, angiotensin receptor blockers (ARBs) and ACE inhibitors (used to treat high blood pressure and congestive heart failure such as Captopril),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 enzyme (COX-2) inhibitors (used to treat pain and inflammation).</p><p>If you have heart failure and are taking sennosides (increase the amount of stools you produce to help you have bowel movements) along with Lanoxin you may have a moderately increased risk of digoxin toxicity.</p><p>Consult a healthcare professional prior to use Senna (for laxative effect)&nbsp; if you are taking cardiac medications such as cardiac glycosides (Lanoxin) or antiarrhythmic medications ( medicines that are used in the treatment of abnormal heart rates or rhythms) which may aggravate electrolytic imbalance.&nbsp;</p><p>Consult a healthcare professional prior to use Panax ginseng if you are taking Lanoxin due to ginseng effect on serum digoxin measurement (digoxin blood level and activity in the body.</p><p>The following medicines<u> reduce the level of Lanoxin</u> in the blood:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antacids (used to treat gastric acidity),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some bulk-forming laxatives (increase the amount of stools you produce to help you have bowel movements),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kaolin-pectin (used to treat diarrhoea),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acarbose (used to treat some types of diabetes),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics: neomycin, penicillamine, rifampicin,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some cytostatic drugs or radiation therapy (used as chemotherapy for cancer treatment),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metoclopramide (a product for treating nausea and vomiting),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulfasalazine &amp; sucralfate (a product to counteract inflammatory diseases of the intestine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenaline (used to treat severe allergic reactions),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; salbutamol/albuterol (a product used to treat asthma),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colestyramine, colestipol (lowers blood cholesterol),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin (used to treat epilepsy),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum</em>) (used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bupropion (used to treat depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-glycoprotein inducers,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; supplemental enteral nutrition (being fed by a feeding tube),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Activated Charcoal,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exenatide, meglitol (used to treat type 2 Diabetes).</p><p>If you are taking Lanoxin along with the following medicines you may have an <u>increased risk</u> <u>of irregular heart rhythm</u>:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intravenous calcium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sympathomimetics such as epinephrine, norepinephrine and dopamine (used to treat heart attack and low blood pressure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Succinylcholine (used in general anesthesia)</p><p>If you are taking Lanoxin and suxamethonium (used to help muscle relaxation and treat short- term paralysis), you may have an <u>increased risk of high potassium levels in the blood</u>.</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antiarrthymics such as dofetilide, sotalol &amp; dronedarone (used to treat a heart rhythm that&#39;s too fast or irregular) ,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parathyroid hormone Analog such as Teriparatide (used to treat osteoporosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid supplement (used to tread hypothyroidism),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-adrenergic blockers and calcium channel blockers,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ivabradine (used to treat heart failure),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mycapssa (octerotide) (used to treat cases with excess growth hormone)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gilenya (fingolimod)&nbsp; (used to treat multiple sclerosis)</p><p><strong>Lanoxin Tablets with food and drink</strong></p><p>This medicine may be taken on an empty stomach or with most meals. However, you should avoid taking Lanoxin tablets with foods that are high in fibre, also known as &#39;dietary fibre&#39; or bran because the level of Lanoxin absorbed by the body can be reduced.</p><p><strong>Pregnancy, breastfeeding and fertility</strong></p><p><u>Pregnancy</u></p><p>Your doctor will prescribe this medicine with caution during pregnancy.</p><p>You may require a higher dose of this medicine if you are pregnant.</p><p>This medicine could be given to the mother to treat abnormally high heart rate and congestive heart failure in the unborn child.</p><p>Side effects of Lanoxin treatment affecting the mother may also affect the unborn child.</p><p><u>Breastfeeding</u></p><p>This medicine is excreted in breast milk, but in very small amounts. Therefore, this medicine can be used by women who are breast-feeding.</p><p><u>Fertility</u></p><p>There is no information available on the effect of Lanoxin on fertility.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Since dizziness and blurred or yellow vision have been reported, you should exercise caution before driving a vehicle, using machinery or participating in dangerous activities.</p><p><strong>Lanoxin tablets contain lactose</strong></p><p>Lanoxin tablets contain lactose (a sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;How to use Lanoxin Tablets</strong></p><p>This medicine is available as a tablet taken orally.</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>Your doctor will have decided how much of this medicine is right for you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It depends on what heart problem you have and how serious it is.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It also depends on your age, weight and how well your kidneys work.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; While you are taking this medicine, your doctor will take regular blood tests. This is to determine how you are responding to treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will adjust your dose based on your blood test results and on how you are responding to treatment. This is why you must strictly adhere to the treatment course prescribed by your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have taken another cardiac glycoside in the past 2 weeks, your doctor may prescribe a lower dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you feel that the effect of this medicine is too strong or too weak, talk to your doctor or pharmacist.</p><p><u>Taking this medicine</u></p><p>You usually take this medicine in two stages:</p><ul><li>&nbsp; Stage 1 - loading dose</li></ul><p>The loading dose gets your Lanoxin levels up to the correct level quickly. You will either:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take one large single dose and then begin your maintenance dose or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take a smaller dose each day for a week and then begin your maintenance dose</p><ul><li>&nbsp;<u>Stage 2 - maintenance dose</u></li></ul><p>After your loading dose you will take a much smaller dose every day, until your doctor tells you to stop.</p><p><em>Oral Administration</em></p><p><u>Adults and children over 10 years</u></p><ul><li>loading dose</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Usually between 0.75 and 1.5 mg as a single dose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For some patients, this may be given in divided doses 6 hours apart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively, between 0.25 and 0.75 mg may be given each day for a week</p><ul><li>&nbsp;maintenance dose</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will decide this, depending on your response to Lanoxin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is usually between 0.125 and 0.25 mg daily</p><p><u>Children under 10 years</u></p><ul><li>loading dose</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is worked out using your child&rsquo;s weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Usually between 0.025 and 0.045 mg per kg of body weight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This should be given in divided doses between 4 and 8 hours apart</p><ul><li>&nbsp;maintenance dose</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor will decide this, depending on your child&rsquo;s response to Lanoxin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is usually a 1/5 (fifth) or a 1/4 (quarter) of the loading dose, to be taken daily</p><p><u>Elderly</u></p><p>Elderly people may be given a lower dose than the usual adult dose. This is because older people may have reduced kidney function. Your doctor will check the levels of Lanoxin in your blood and may change your dose if necessary.</p><p><strong>If you use more Lanoxin Tablets than you should</strong></p><p>If you have taken too much of the Lanoxin tablets or a child has taken the medicine by accident, contact your doctor, hospital or poison centre to evaluate the risks and get more information.</p><p>The main symptoms of Lanoxin toxicity are heart rhythm disturbances and gastrointestinal symptoms which may happen before heart rhythm disturbances. Gastrointestinal symptoms include loss of appetite, nausea and vomiting. Other symptoms of Lanoxin toxicity include dizziness, fatigue, a general feeling of being unwell and various neurological disturbances including visual disturbances (more yellow-green than usual). The neurological and visual symptoms may persist even after other signs of toxicity have been resolved. In chronic toxicity, non-heart related symptoms, such as weakness and a general feeling of being unwell, may be the main symptoms.</p><p><strong>If you forget to use Lanoxin Tablets</strong></p><p>Do not take a double dose to make up for the forgotten dose.</p><p><strong>If you stop using Lanoxin Tablets</strong></p><p>Your doctor will tell you how long you should take Lanoxin. Do not stop your treatment early without consulting your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;&nbsp;&nbsp;Possible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you get any of the following, talk to your specialist doctor straight away or seek urgent medical advice:</p><p><u>Very rare (may affect up to 1 in 10,000 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations, chest pain, shortness of breath or sweating. These can be symptoms of a serious heart problem caused by new irregular heartbeats</p><p>Other side effects may include:</p><p><u>Common (may affect up to 1 in 10 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions of the skin may occur (rash, urticaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart-beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, vomiting, diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; central nervous system disturbances such as dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances (blurred or yellow vision)</p><p><u>Uncommon (may affect up to 1 in 100 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p><u>Very rare (may affect up to 1 in 10,000 people)</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in blood platelets (symptoms include bruises and nose bleeds)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (anorexia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; psychosis, apathy, confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain caused by lack of blood supply or damage to your intestines (ischaemia and necrosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged breast tissue in men (gynaecomastia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of energy (fatigue), a general feeling of being unwell and weakness</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.&nbsp;&nbsp;How to store Lanoxin Tablets</strong></p><ul><li>&nbsp; Keep out of the reach and sight of children.</li><li>&nbsp;Do not use Lanoxin after the expiry date on carton or blister (Exp.). The expiry date refers to the last day of that month.</li><li>&nbsp;Store below 25&deg;C.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Lanoxin Tablets contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; The active ingredient is digoxin, each tablet contains 0.125 mg (125 micrograms).</p><p>&middot;&nbsp;&nbsp;&nbsp; The other ingredients are lactose monohydrate, maize starch, modified maize starch, rice starch, magnesium stearate and Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Lanoxin Tablets looks like and contents of the pack
 Within the carton are blisters that contains 100 white tablets or a bottle that contains 500 white tablets. A white, round, flat tablet debossed “DO12" on the one side and plain on the other side.

Not all pack sizes and pack types may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong></p><p><strong>Marketing Authorisation Holder:</strong></p><p>Aspen Pharma Trading Limited</p><p>3016 Lake Drive,</p><p>Citywest Business Campus, Dublin 24,</p><p>Ireland</p><p><strong>Manufactured by: </strong>Aspen Bad Oldesloe GmbH, Industriestrasse 32-36, D 23843 Bad Oldesloe, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {June /2023}, Version number {5}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1.&nbsp;&nbsp;&nbsp;</strong><strong>ما هو لانوكسين وما هي دواعي استخدامه&nbsp;</strong></p><p dir="RTL">تحتوي أقراص لانوكسين على المادة الفعالة ديجوكسين، والتي تنتمي إلى مجموعة من الأدوية تُدعى الغليكوزيدات القلبية. وهي تستخدم لعلاج الاضطرابات النظمية وحالات قصور القلب. واضطراب النظم هو عدم انتظام في ضربات القلب والتي تتسبب في تخطي القلب لإحدى النبضات أو عدم الانتظام في نبضات القلب أو نبض القلب بسرعة غير مناسبة. يعمل هذا الدواء عن طريق تصحيح ضربات القلب غير المنتظمة إلى الإيقاع المنتظم ويعزز قوة ضربات القلب، لذا يفيد في حالات الفشل القلبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2.&nbsp; &nbsp;</strong><strong>ما الذي تحتاج لمعرفته قبل استخدام أقراص لانوكسين</strong></p><p dir="RTL"><strong>لا تستخدم أقراص لانوكسين في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بحساسية لمادة الديجوكسين، أو لأي غليكوزيدات قلبية أخرى أو لأي من مكونات الدواء الأخرى (المذكورة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمشاكل قلبية خطيرة، مثل توصيل النبضات الكهربية في القلب، خاصةً إذا كان لديك تاريخ من نوبات ستوكس آدامز (فقدان وعي مفاجئ وقصير ناجم عن تغير مفاجئ في معدل ضربات أو إيقاع القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدم انتظام ضربات القلب الذي تسبب فيه التسمم بمادة الغليكوزيد القلبية أو الحالات المرضية مثل متلازمة وولف- باركنسون- وايت.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اعتلال عضلة القلب الانسدادي (تضخم عضلة القلب).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل استخدام هذا الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم هذا الدواء، فقد يطلب منك الطبيب إجراء اختبارات منتظمة للدم من أجل تحديد كمية اللانوكسين في الدم. وقد يكون هذا مفيدًا في حالات مرضى الاضطرابات الكلوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتسمم الديجوكسين، فقد يؤدي ذلك إلى أشكال مختلفة من اضطرابات نظم القلب، بعضها يشبه اضطرابات النظم التي وصف المنتج لعلاجها.</p><p dir="RTL">-&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;إذا كنت تعاني من عدم انضباط نظم القلب (إحصار القلب) وكنت تستخدم هذا الدواء، فعليك بالاتصال بالطبيب فورًا إذا شعرت بعرض واحد أو أكثر من الأعراض التالية: الإغماء أو الفقدان المؤقت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً باضطراب جيبي أذيني (اضطراب في توصيل النبضات الكهربائية في القلب مثل متلازمة العقدة الجيبية المريضة)، ففي بعض مرضى الاضطراب الجيبي الأذيني، قد يتسبب هذا الدواء في تباطؤ أو عدم انتظام ضربات القلب. في بعض الأحيان، قد يتسبب ذلك في الإجهاد، والضعف، والدوّار، وعند التباطؤ الشديد في ضربات القلب قد تفقد الوعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت مؤخراً من أزمة قلبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند حدوث قصور في القلب مع وجود تجميع للبروتين غير الاعتيادي في أنسجة القلب (الداء النشواني القلبي)، فقد تكون هناك حاجة إلى وصف علاج بديل من قبل الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب عضلة القلب، فقد يتسبب هذا في تضييق الأوعية (تضييق الأوعية الدموية) في بعض الحالات النادرة. وقد يصف لك الطبيب دواءً مختلفًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض البري بري (وهو المرض الذي ينتج عن نقص في فيتامين ب-1).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب التامور المضيق (التهاب الكيس الذي يحتوي على القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم الأدوية المدرّة للبول (العقاقير التي تحض على إنتاج البول والمساعدة في تقليل كمية الماء الموجودة في الجسم) وذلك باستخدام أو دون استخدام مثبطات الإنزيم المحول للأنجيوتنسين (المستخدمة في علاج ضغط الدم المرتفع)، فقد يصف لك الطبيب جرعة أقل من اللانوكسين. لا تتوقف عن تناول لانوكسين دون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تقوم بإجراء اختبار ECG (مخطط كهربائية القلب)، فعليك بإخبار الشخص الذي يقوم بإجراء الاختبار لك بأنك تستخدم اللانوكسين لأنه قد يؤثر على فحوى النتائج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمرض تنفسي (رئوي) حاد (حيث قد ترتفع لديك الحساسية من اللانوكسين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستويات الأوكسجين الذي يصل إلى أجزاء محددة من جسمك، أو انخفاض مستويات البوتاسيوم، مستويات منخفضة لدرجة غير طبيعية من المغنيسيوم أو ارتفاع مستويات الكالسيوم في دمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني مرضًا في الغدة الدرقية (مثل الخمول أو النشاط المفرط في الغدة الدرقية) وذلك لأنك قد يكون مطلوبًا لك إجراء تغيير على الجرعة التي تتعاطاها من هذا الدواء.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاباً بمتلازمة سوء الامتصاص (لا يمكنك امتصاص المعادن من الطعام على النحو الملائم) أو خضعت من قبل لجراحة إعادة ترميم المعدة والأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستتعرض للعلاج بالصدمات الكهربائية لتصحيح ضربات القلب غير المنتظمة.</p><p dir="RTL"><strong>الأدوية الأخرى وأقراص لانوكسين </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. قد يؤدي استخدام أدوية متعددة في بعض الأحيان إلى عواقب ضارة أو قد يؤدي إلى تفاعلات غير مرغوب بها.</p><p dir="RTL">وقد يتزايد مستوى الحساسية للانوكسين بالأدوية التي تعمل على تقليل مستوى البوتاسيوم في الدم. ومنها:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المدرة للبول،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الليثيوم (مضادات اكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتجات المعتمدة على الستيرويد القشري،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكاربينوكسولون (هو منتج يعمل على تقوية الغشاء المخاطي المعدي).</p><p dir="RTL">تعمل الأدوية التالية <u>على زيادة مستوى اللانوكسين في الدم</u> والذي قد يتسبب في زيادة مخاطر التعرض للتسمم:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستحضرات معينة تؤثر على القلب: أميودارون، فليكاينيد، برازوسين، بروبافينون، كوينيدين، كابتوبريل،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاناجليفلوزين (يستخدم لعلاج مرض السكري من النوع 2)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيريثروميسين، كلاريثروميسين، تتراسايكلاين، جنتاميسين، تريميثوبريم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داكلاتاسفير (يستخدم بالإقتران مع أدوية أخرى لعلاج التهاب الكبد الفيروسي سي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فليبانسرين (يستخدم في علاج إنخفاض الرغبة الجنسية عند النساء اللاتي لم يصلن إلى سن اليأس)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيسافوكونازول (يستخدم في علاج الالتهابات الفطرية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيتراكونازول (دواء يستخدم في علاج الالتهابات الفطرية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفاكافتور (يستخدم في علاج التليف الكيسي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبيرونولاكتون ( دواء يزيد كمية البول التي تخرجها)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألبرازولام (مهدئ قد يُستخدم في علاج القلق)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إندوميثاسين (يُستخدم في علاج الالتهاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كويناين (قد يُستخدم في الوقاية من عدوى الملاريا)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبانثيلين (يستخدم في الوقاية من التشنجات العضلية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميرابيجرون (يستخدم في علاج فرط نشاط المثانة الذي يتسبب في رغبة ملحة مفاجئة للتبول ينتج عنها تبول لا إرادي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفازودون (مضاد للاكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين (يعمل على تقليل مستوى الكوليسترول في الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (كابت مناعة يُستخدم عادة في الوقاية من رفض الأعضاء المزورعة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيبوبروستينول (يُستخدم في علاج ارتفاع الضغط الشرياني الرئوي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولفابتان (يُستخدم في علاج انخفاض مستويات الصوديوم في الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كونيفابتان (يُستخدم في علاج انخفاض مستويات الصوديوم في الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كارفيديلول (يُستخدم في علاج الفشل القلبي الاحتقاني الطفيف إلى الحاد وارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير و ساكوينافير (يُستخدم في علاج عدوى فيروس العوز المناعي البشري والإيدز)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاليبرفير (يُستخدم في علاج عدوى التهاب الكبد الفيروسي سي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درونيدارون (يُستخدم في علاج ضربات القلب غير المنتظمة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رانولازاين (يُستخدم في علاج آلام الصدر)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيميبريفير (يستخدم بالإقتران مع أدوية أخرى لعلاج التهاب الكبد الفيروسي سي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيلميسارتان (يُستخدم في علاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاباتينيب (يُستخدم في علاج سرطان الثدي)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيكاجريلور (يُستخدم في الوقاية من الأزمات أو السكتات القلبية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل (يُستخدم في علاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلوديباين (يُستخدم في علاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تياباميل (يُستخدم في علاج آلام الصدر)،</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>فانديتانيب (يستخدم في علاج بعض أنواع سرطان الغدة الدرقية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيلباتاسفير (يستخدم بالإقتران مع أدوية أخرى لعلاج التهاب الكبد الفيروسي سي)،</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>مثبطات البروتين السكري-P.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوكلاكس (يستخدم في علاج المرضى المصابين بسرطان الدم اللمفاوي المزمن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيمورافينيب (يستخدم في علاج المرضى البالغين المصابين بنوع من السرطان يُطلق عليه الميلانوما)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات مضخة البروتون مثل رابيبرازول (تستخدم في تخفيف أعراض ارتجاع الحمض أو الارتداد المعدي المريئي)</p><p dir="RTL">قد تعمل الأدوية التالية على <u>زيادة أو لا يكون لها تأثير على مستويات اللانوكسين</u> في الدم:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نيفاديباين، وديلتيازيم، وأدوية إحصار مستقبلات الأنجيوتنسين (ARBs) ومثبطات الإنزيم المحول للأنجيوتنسين (يُستخدم في علاج ارتفاع ضغط الدم وقصور القلب الاحتقاني) مثل كابتوبريل ،</p><p dir="RTL"><strong>-</strong> أدوية مضادات الالتهاب اللاستيرويدية (NSAID) ومثبطات إنزيم سايكلوإكسيجيناز 2 (COX-2) (تُستخدم في علاج الآلام والالتهاب).</p><p dir="RTL">إذا كنت تعاني من قصور القلب وتتناول أدوية السينوزايد (تعمل على زيادة كمية البراز التي تخرج من الجسم للمساعدة في زيادة حركة الأمعاء) مع اللانوكسين، فقد تكون هناك زيادة معتدلة في خطورة التعرض للتسمم بالديجوكسين.</p><p dir="RTL">استشر أخصائي الرعاية الصحية قبل استخدام سينا (للتأثير الملين) إذا كنت تتناول أدوية للقلب مثل الغليكوزيدات القلبية (لانوكسين) أو مضادات اضطراب النظم (أدوية تستخدم في علاج معدل ضربات القلب أو النظم غير الطبيعي) التي قد تسبب في تفاقم اختلال الإلكتروليت.&nbsp;</p><p dir="RTL">استشر أخصائي الرعاية الصحية قبل استخدام بناكس جنسنج إذا كنت تتناول لانوكسين نظراً لتأثير الجنسنج على قياس ديجوكسين المصل (مستوى الديجوكسين بالدم ونشاطه في الجسم).&nbsp; &nbsp;</p><p dir="RTL">تعمل الأدوية التالية على<u> تقليل مستوى اللانوكسين</u> في الدم:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة (تستخدم لعلاج الحموضة المعدية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الملينات المكونة للكتل (تعمل على زيادة كمية البراز التي ينتجها الجسم للمساعدة في تحركات الأمعاء)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاولين-بكتين (يُستخدم في علاج الإسهال)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكاربوز (يُستخدم في علاج بعض أنواع السكري)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحيوية: نيومايسين، بنسيلامين، ريفامبيسين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض عقاقير السايتوستاتيك أو العلاج الإشعاعي (تُستخدم في المعالجة الكيميائية للسرطان)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتوكلوبرمايد (منتج لعلاج الغثيان والقيء)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سالفاسالازين وسوكرالفات (منتج لمجابهة الأمراض الالتهابية للأمعاء)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدرينالين (يُستخدم في علاج ردود الفعل التحسسية الوخيمة)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سالبوتامول / ألبوتيرول (مستحضر يُستخدم في علاج الربو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوليستيراماين، كوليستيبول (يعمل على تقليل مستوى الكوليسترول في الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (يُستخدم في علاج الصرع)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة القديس يوحنا المثقبة (هايبيريكم بيرفراتم) (يُستخدم في علاج الاكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيبروبيون (يُستخدم في علاج الاكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محفزات البروتين السكري-P،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغذية المعوية التكميلية (حيث تتم التغذية بواسطة أنبوب للإطعام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفحم المنشط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيكسيناتايد ، ميجليتول (لعلاج داء السكري من النوع الثاني)</p><p dir="RTL">إذا كنت تتناول اللانوكسين مع الأدوية التالية، فقد تكون هناك خطورة متزايدة <u>في التعرض للنظم غير المنتظم في ضربات القلب</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكالسيوم داخل الوريد &nbsp;</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>محصرات البيتا</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المحاكيات الودية مثل الأدرينالين والنورادرينالين والدوبامين (تُستخدم في علاج الأزمات القلبية وانخفاض ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكسينيل كولين (يستخدم في التخدير العام)</p><p dir="RTL">إذا كنت تتناول لانوكسين وساكساميثونيوم (يُستخدم في المساعدة على إرخاء العضلات وعلاج الشلل قصير المدى)، فقد يرتفع احتمال <u>تعرضك لارتفاع مستويات البوتاسيوم في الدم</u></p><p dir="RTL">على وجه الخصوص ، أخبر طبيبك أو الصيدلي أو الممرضة إذا كنت تتناول أيًا من الأدوية التالية:</p><p dir="RTL"><em>-&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>&nbsp;مضادات اضطراب النظم<em> </em>مثل دوفيتيليد ، سوتالول ودرونيدارون (تستخدم لعلاج ضربات القلب السريعة أو غير<em>&nbsp;</em><em>&nbsp;</em>المنتظمة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون الغدة الجار درقية التناظرية مثل تيريباراتيد (يستخدم لعلاج هشاشة العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكمل الغدة الدرقية (يستخدم لعلاج قصور الغدة الدرقية) ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا الأدرينالية وحاصرات قنوات الكالسيوم ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ايفابرادين (يستخدم لعلاج قصور القلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميكابسسا (أوكتيروتيد) (يستخدم لعلاج الحالات التي تحتوي على هرمون النمو الزائد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جيلينيا (فينجوليمود) (تستخدم لعلاج التصلب المتعدد).<em>&nbsp;</em></p><p dir="RTL"><strong>أقراص لانوكسين مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول هذا الدواء على معدة خاوية أو مع معظم الوجبات. إلا أنه يجب تجنب تناول أقراص لانوكسين مع الأطعمة ذات المحتوى العالي من الألياف، والتي تُعرف أيضاً بالألياف الغذائية ، أو النخالة &nbsp;وذلك لاحتمال انخفاض مستوى اللانوكسين الذي يمتصه الجسم.</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">سيصف الطبيب لكِ هذا الدواء بحذر أثناء الحمل.</p><p dir="RTL">قد يتطلب الأمر تناول جرعة عالية من هذا الدواء إذا كنتِ حاملاً.</p><p dir="RTL">يمكن إعطاء هذا الدواء للأم لعلاج ارتفاع معدل ضربات القلب بشكل غير طبيعي وحالات قصور القلب الاحتقانية في الأطفال التي لم تُولد بعد.</p><p dir="RTL">قد يكون للآثار الجانبية للعلاج باللانوكسين التي تؤثر على الأم، تأثيرًا أيضًا على الطفل الذي لم يُولد بعد.</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">يُفرز هذا الدواء في لبن الأم ولكنه يظهر بكميات قليلة للغاية. وعليه، يُمكن استخدام هذا الدواء بواسطة السيدات اللاتي يرضعن رضاعة طبيعية.</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">لا توجد معلومات متوفرة حول تأثير لانوكسين على الخصوبة.</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">نظراً لأنه قد تم الإبلاغ عن حدوث الدوار وتشوش الرؤية أو الرؤية الصفراء، فينبغي عليك توخي الحذر قبل قيادة المركبات أو استخدام الآلات أو المشاركة في الأنشطة الخطرة.</p><p dir="RTL"><strong>أقراص لانوكسين تحتوي على اللاكتوز</strong></p><p dir="RTL">أقراص لانوكسين تحتوي على اللاكتوز (نوع من السكر). إذا أخبرك طبيبك أنك تعاني من حساسية مفرطة لبعض أنواع السكر، اتصل بطبيبك قبل تناول هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3.&nbsp;&nbsp;</strong><strong>كيفية استخدام أقراص لانوكسين</strong></p><p dir="RTL">يتوفر هذا الدواء في صيغة أقراص يؤخد عن طريق الفم.</p><p dir="RTL">تناول هذا الدواء دائماً على النحو الذي يصفه طبيبك. استشر طبيبك إذا لم تكن متأكداً.</p><p dir="RTL">سيقرر الطبيب الكمية المناسبة لك من هذا الدواء:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعتمد ذلك على مشكلة القلب التي تعاني منها ومدى خطورتها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما يعتمد أيضًا على عمرك ووزنك ومستوى كفاءة عمل الكليتين لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء تناولك لهذا الدواء سيجري الطبيب بعض اختبارات الدم المنتظمة لك. وهذا لتحديد مدى استجابتك لهذا العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعدِّل الطبيب الجرعة التي تتناولها بناءً على نتائج اختبارات الدم الخاصة بك ومدى استجابتك للعلاج. ولهذا السبب يجب عليك الالتزام بدقة بجرعة العلاج الموصوفة لك من قبل الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تناولت جرعة أخرى من الغليكوزيد القلبي في الأسبوعين السابقين، فقد يصف لك الطبيب جرعة أقل من الدواء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا شعرت بأن تأثير هذا الدواء قوي للغاية أو ضعيف للغاية، عليك بالتحدث مع طبيبك أو الصيدلي.</p><p dir="RTL"><u>تناول هذا الدواء</u></p><p dir="RTL">عادة ما يتم تناول هذا الدواء على مرحلتين:</p><ul dir="rtl"><li>&nbsp;المرحلة الأولى - جرعة التحميل</li></ul><p dir="RTL">تعمل جرعة التحميل على رفع مستويات لانوكسين لديك إلى المستوى المناسب سريعًا. سيكون أمامك طريقة مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول جرعة واحدة كبيرة وبعد ذلك البدء في جرعة المداومة (الصيانة) أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول جرعة أقل يومياً لمدة أسبوع ثم البدء في جرعة المداومة (الصيانة)</p><ul dir="rtl"><li>&nbsp;<u>المرحلة الثانية - جرعة المداومة (الصيانة)</u></li></ul><p dir="RTL">بعد تناولك لجرعة التحميل، ستتناول جرعة أصغر كثيرًا كل يوم إلى أن يخبرك طبيبك بالتوقف.</p><p dir="RTL">التناول عن طريق الفم</p><p dir="RTL"><u>البالغون والأطفال أكبر من </u><u>10</u><u> سنوات</u></p><ul dir="rtl"><li>&nbsp; &nbsp;جرعة التحميل</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما بين 0.75 و1.5 ملغ كجرعة مفردة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة لبعض المرضى، قد تؤخذ هذه الجرعة في جرعات مقسمة كل 6 ساعات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو قد يؤخذ ما بين 0.25 و0.75 ملغ كل يوم لمدة أسبوع</p><ul dir="rtl"><li>&nbsp; جرعة المداومة</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتقرير ذلك بناءً على مدى استجابتك للانوكسين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما تكون ما بين 0.125 و0.25 ملغ يومياً</p><p dir="RTL"><u>الأطفال أقل من </u><u>10</u><u> أعوام</u></p><ul dir="rtl"><li>&nbsp; &nbsp; جرعة التحميل</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تحديد ذلك بحسب وزن الطفل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما تكون الجرعة بين 0.025 و0.045 ملغ لكل كجم من وزن الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تؤخذ هذه الكمية على جرعات مقسمة يفصل بين كل منها ما بين 4 و8 ساعات</p><ul dir="rtl"><li>&nbsp;جرعة المداومة</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقرر الطبيب ذلك، وذلك بحسب استجابة طفلك لـلانوكسين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادة ما تكون الجرعة 1/5 (خُمس) أو 1/4 (ربع) جرعة التحميل، وتؤخذ يومياً</p><p dir="RTL"><u>كبار السن</u></p><p dir="RTL">قد يتم إعطاء كبار السن جرعة أقل من جرعة البالغين المعتادة. وذلك يرجع إلى أن كبار السن قد يكون لديهم انخفاض في وظائف الكلى. سيتحقق الطبيب من مستويات اللانوكسين في الدم وقد يغيِّر الجرعة عند الضرورة.</p><p dir="RTL"><strong>في حالة استخدام كمية أكبر من اللازم من أقراص لانوكسين:&nbsp;</strong></p><p dir="RTL">في حالة تناول كمية أكبر من اللازم من أقراص لانوكسين، أو في حالة تناول طفل الدواء عن طريق الخطأ، اتصل بطيببك، أو المستشفى، أو مركز السموم لتقييم المخاطر والحصول على مزيد من المعلومات.</p><p dir="RTL">الأعراض الرئيسية لتسمم لانوكسين هي اضطرابات نظم القلب وأعراض معدية معوية قد تحدث قبل اضطرابات نظم القلب. تتضمن الأعراض المعدية المعوية فقدان الشهية والغثيان والقيء. الأعراض الأخرى التي قد تظهر للتسمم باللانوكسين تتضمن الدّوار، والإجهاد، والشعور العام بالاعتلال واضطرابات عصبية مختلفة تتضمن اضطرابات بصرية (تزايد اللونين الأصفر والأخضر عن المعتاد). وقد تستمر أعراض الأمراض العصبية والأعراض البصرية في الظهور حتى بعد علاج علامات السمية الأخرى. في حالة السمية المزمنة، قد تكون الأعراض الرئيسية أعراض غير متصلة بالقلب، مثل الضعف، وشعور عام بالاعتلال.</p><p dir="RTL"><strong>في حال نسيت استخدام أقراص لانوكسين</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا توقفت عن استخدام أقراص</strong><strong> </strong><strong>لانوكسين</strong></p><p dir="RTL">سيخبرك طبيبك بالفترة التي ينبغي عليك تعاطي لانوكسين خلالها.&nbsp; لا تكرر تتوقف عن العلاج مبكرًا دون استشارة الطبيب.</p><p dir="RTL">إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4.&nbsp;&nbsp;</strong><strong>الآثار الجانبية المحتملة&nbsp;</strong></p><p dir="RTL">مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p dir="RTL">إذا شعرت بأي من الأعراض التالية، تحدث مع طبيبك على الفور أو اطلب الحصول على المشورة الطبية العاجلة:</p><p dir="RTL"><u>الآثار الجانبية النادرة جداً (قد تصيب </u><u>1</u><u> من كل </u><u>10000</u><u> شخص)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان أو آلام الصدر أو ضيق النفس أو التعرق. قد تكون هذه الأعراض خاصة بمشكلة قلبية خطيرة نتيجة لنبضات القلب غير المنتظمة الجديدة.</p><p dir="RTL">من الآثار الجانبية الأخرى:</p><p dir="RTL"><u>شائعة (قد تؤثر على </u><u>1</u><u> من كل </u><u>10</u><u> أشخاص)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث ردود فعل تحسسية للجلد (الطفح الجلدي والشرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات القلب بمعدل غير طبيعي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والقيء والإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النظام العصبي المركزي مثل الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطرابات البصرية (تشوش الرؤية أو الرؤية الصفراء)</p><p dir="RTL"><u>غير شائعة (قد تؤثر على </u><u>1</u><u> من كل </u><u>100</u><u> شخص)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL"><u>الآثار الجانبية النادرة جداً (قد تصيب </u><u>1</u><u> من كل </u><u>10000</u><u> شخص)</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (أعراض تتضمن كدمات ونوبات نزيف من الأنف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية (القهم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذهان والخمول والتخليط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة ناتج عن انخفاض إمداد الدم أو تضرر الأمعاء (الإقفار والنخر)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم أنسجة الثدي في الرجال (التثدي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الطاقة (الإرهاق)، شعور عام بالاعتلال والضعف</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5.&nbsp;&nbsp;</strong><strong>كيفية تخزين أقراص لانوكسين</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;يُحفظ بعيداً عن متناول ومرأى الأطفال.</li><li>&nbsp; &nbsp;لا تستخدم لانوكسين بعد تاريخ انتهاء الصلاحية الموضح على العبوة الكرتونية الخارجية أو الشريط (Exp). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</li><li>&nbsp;يخزن في درجة حرارة أقل من 25 درجة مئوية.</li><li>&nbsp; &nbsp;لا يجب التخلص من أي أدوية في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الذي تحتويه أقراص لانوكسين</strong></p><ul dir="rtl"><li>&nbsp; المادة الفعالة هي ديجوكسين، يحتوي كل قرص على 0.125 ملغ (125 ميكروغرام).</li><li>&nbsp; المكونات الأخرى هي لاكتوز أحادي الهيدرات، نشا ذرة، نشا ذرة معدل، نشا أرز، ستيارات المغنيسيوم وماء منقى.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تبدو أقراص لانوكسين وما هي محتويات العبوة</strong></p><p dir="RTL">تحتوي العبوة الكرتونية على أشرطة تحتوي على 100 قرص أبيض أو عبوة تحتوي على 500 قرص أبيض. قرص أبيض مستدير محفور على أحد جانبيه &quot;DO12&quot; والجانب الآخر فارغ.</p><p dir="RTL">قد لا تكون جميع أحجام أو أنواع العبوات مسوقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق والمُصَّنع</strong></p><p dir="RTL"><strong>مالك حق التسويق: </strong></p><p dir="RTL">أسبن فارما تريدينغ المحدودة</p><p dir="RTL">3016 ليك درايف،</p><p dir="RTL">مجمع سيتي ويست للأعمال،</p><p dir="RTL">دبلن 24،</p><p dir="RTL">أيرلندا</p><p dir="RTL"><strong>تم التصنيع بواسطة</strong>: شركة أسبن باد أولدسلو المحدودة المنطقة الصناعية 32-36، دي - 23843 باد أولدسلو، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في {يونيو/2023} ، رقم النسخة {5}.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lanoxin 0.125 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Digoxin Ph Eur 0.125 mg/tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardiac failure</u></p><p>Digoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. Its therapeutic benefit is greatest in those patients with ventricular dilatation.</p><p>Digoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.</p><p><u>Supraventricular arrhythmias</u></p><p>Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic</p><p>atrial flutter and fibrillation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology:</u></p><p>The dose of digoxin for each patient has to be tailored individually according to age, lean body weight and renal function.</p><p>Suggested doses are intended only as an initial guide.</p><p>In cases where cardiac glycosides have been taken in the preceding two weeks the recommendations for initial dosing of a patient should be reconsidered and a reduced dose is advised.</p><p>The difference in bioavailability between injectable digoxin and oral formulations must be considered when changing from one dosage form to another. For example if patients are switched from oral to the I.V. formulation the dosage should be reduced by approximately 33%.</p><p><u>Adults and paediatric populations over 10 years</u></p><p><em>Rapid oral loading:</em></p><p>If medically appropriate, rapid digitalisation may be achieved in a number of ways, such as 750 to 1500 micrograms (0.75 to 1.5 mg) as a single dose.</p><p>Where there is less urgency, or greater risk of toxicity e.g. in the elderly, the oral loading dose should be given in divided doses six hours apart, with approximately half the total dose given as the first dose. Clinical response should be assessed before giving each additional dose (see Section 4.4).</p><p><em>Slow oral loading:</em></p><p>In some patients, example those with mild heart failure, digitalisation may be achieved more slowly with doses of 250 to 750 micrograms (0.25 to 0.75 mg) daily for one week followed by an appropriate maintenance dose. A clinical response should be seen within one week.</p><p><em>Maintenance dose:</em></p><p>The maintenance dosage should be based upon the percentage of the peak body stores lost each day through elimination. The choice between slow and rapid oral loading depends on the clinical state of the patient and the urgency of the condition.</p><p>The following formula has had wide clinical use:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Maintenance dose = Peak body stores x <u>daily loss in percent</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>Where:</p></td><td colspan="2" style="vertical-align:top"><p>Peak body stores = personalised loading dose</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>daily loss (in percent) = 14 + creatinine clearance (Ccr)/5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p>Ccr is creatinine clearance corrected to 70 kg bodyweight or 1.73 m<sup>2</sup> body surface area. If only serum creatinine (Scr) concentrations are available, a Ccr (corrected to 70 kg bodyweight) may be estimated in men as</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ccr =</p></td><td style="vertical-align:top"><p><u>(140 - age)</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Scr (in mg/100 ml)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p><u>NOTE:</u> Where serum creatinine values are obtained in micromol/l, these may be converted to mg/100 ml (mg %) as follows:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Scr(mg/100 ml) =</p></td><td style="vertical-align:top"><p><u>S</u>cr<u> </u><u>(micromol/l) x 113.12</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10,000</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>=</p></td><td style="vertical-align:top"><p><u>S</u>cr<u> </u><u>(micromol/l)</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>88.4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Where 113.12 is the molecular weight of creatinine.</p><p><em>For women</em>, this result should be multiplied by 0.85.</p><p><em>N.B. </em>These formulae cannot be used for creatinine clearance in children.</p><p>In practice, this will mean that most patients with heart failure will be maintained on 125 to 250 micrograms (0.125 to 0.25 mg) digoxin daily; however in those who show increased sensitivity to the adverse effects of digoxin, a dose of 62.5 micrograms (0.0625 mg) daily or less may suffice.</p><p>Conversely, some patients may require a higher dose.</p><p><u>Neonates, infants and paediatric populations up to 10 years of age</u></p><p>If cardiac glycosides have been given in the two weeks preceding commencement of digoxin therapy, it should be anticipated that optimum loading doses of digoxin will be less than those recommended below.</p><p>In the newborn, particularly in the premature infant, renal clearance of digoxin is diminished and suitable dose reductions must be observed, over and above general dosage instructions.</p><p>Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight or body surface area, as indicated in the schedule below. Children over ten years of age require adult dosages in proportion to their body weight.</p><p><em>Oral loading dose:</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Preterm neonates less than 1.5 kg</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>25 micrograms/kg per 24 h.</p></td></tr><tr><td style="vertical-align:top"><p>Preterm neonates 1.5 kg to 2.5 kg</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>30 micrograms/kg per 24 h.</p></td></tr><tr><td style="vertical-align:top"><p>Term neonates to 2 years</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>45 micrograms/kg per 24 h.</p></td></tr><tr><td style="vertical-align:top"><p>2 to 5 years</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>35 micrograms/kg per 24 h.</p></td></tr><tr><td style="vertical-align:top"><p>5 to 10 years</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>25 micrograms/kg per 24 h.</p></td></tr></tbody></table><p>The loading dose should be administered in divided doses with approximately half the total dose given as the first dose and further fractions of the total dose given at intervals of 4 to 8 h, assessing clinical response before giving each additional dose.</p><p><em>Maintenance dose:</em></p><p>The maintenance dose should be administered in accordance with the following schedule:</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Preterm neonates:</p></td></tr><tr><td style="vertical-align:top"><p>daily dose = 20 % of 24 h loading dose.</p></td></tr><tr><td style="vertical-align:top"><p>Term neonates and children up to 10 years:</p></td></tr><tr><td style="vertical-align:top"><p>daily dose = 25 % of 24 h loading dose.</p></td></tr></tbody></table><p>These dosage schedules are meant as guidelines and careful clinical observation and monitoring of serum digoxin levels (see Section 4.4) should be used as a basis for adjustment of dosage in these paediatric patient groups.</p><p><u>Elderly</u></p><p>The possibility of reduced renal function and lower lean body mass should be taken into account when dealing with elderly patients. If necessary, the dosage should be reduced and adjusted to the changed pharmacokinetics to prevent elevated serum dioxin levels and the risk of toxicity. The serum dioxin levels should be checked regularly and hypokalaemia should be avoided.</p><p><u>Renal impairment</u></p><p>The dosing recommendations should be reconsidered if patients are elderly or there are other reasons for the renal clearance of digoxin being reduced. A reduction in both initial and maintenance doses should be considered (See Section 4.4).</p><p><u>Method of administration:</u></p><p>For oral use only.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Digoxin is contraindicated in:
-	intermittent complete heart block or second degree atrioventricular block, especially if there is a history of Stokes-Adams attacks.
-	arrhythmias caused by cardiac glycoside intoxication.
-	supraventricular arrhythmias associated with an accessory atrioventricular pathway, as in the Wolff-Parkinson-White syndrome, unless the electrophysiological characteristics of the accessory pathway and any possible deleterious effect of digoxin on these characteristics have been evaluated. If an accessory pathway is known or suspected to be present and there is no history of previous supraventricular arrhythmias, digoxin is similarly contraindicated.
-	ventricular tachycardia or ventricular fibrillation.
-	hypertrophic obstructive cardiomyopathy, unless there is concomitant atrial fibrillation and heart failure but even then caution should be exercised if digoxin is to be used.
-	hypersensitivity to the active substance, other digitalis glycosides or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Monitoring</u></p><p>Patients receiving digoxin should have their serum electrolytes and renal function (serum creatinine concentration) assessed periodically; the frequency of assessments will depend on the clinical setting.</p><p>Serum concentrations of digoxin may be expressed in Conventional Units of nanograms/ml or SI Units of nanomol/l. To convert nanograms/ml to nanomol/l, multiply nanograms/ml by 1.28.</p><p>The serum concentration of digoxin can be determined by radioimmunoassay. Blood should be taken six hours or more after the last dose of digoxin.</p><p>There are no rigid guidelines as to the range of serum concentrations that are most efficacious. Post hoc analyses of heart failure patients in the Digitalis Investigation Group trial suggest that the optimal trough digoxin serum level may be 0.5 nanogram/ml (0.64 nanomol/l) to 1.0 nanogram/ml (1.28 nanomol/l).</p><p>Digoxin toxicity is more commonly associated with serum digoxin concentrations greater than</p><p>2 nanogram/ml. However, serum digoxin concentration should be interpreted in the clinical context. Toxicity may occur with lower digoxin serum concentrations. In deciding whether a patient&#39;s symptoms are due to digoxin, the clinical state together with the serum potassium level and thyroid function are important factors (see Section 4.9).</p><p>Determination of the serum digoxin concentration may be very helpful in making a decision to treat with further digoxin, but other glycosides and endogenous digoxin-like substances, including metabolites of digoxin, can interfere with the assays that are available and one should always be wary of values which do not seem commensurate with the clinical state of the patient. Observations while temporary withholding digoxin might be more appropriate.</p><p><u>Arrhythmias</u></p><p>Arrhythmias may be precipitated by digoxin toxicity, some of which can resemble arrhythmias for which the drug could be advised. For example, atrial tachycardia with varying atrioventricular block requires particular care as clinically the rhythm resembles atrial fibrillation.</p><p>Many beneficial effects of digoxin on arrhythmias result from a degree of atrioventricular conduction blockade. However, when incomplete atrioventricular block already exists the effects of a rapid progression in the block should be anticipated. In complete heart block the idioventricular escape rhythm may be suppressed.</p><p><u>Sinoatrial disorder</u></p><p>In some cases of sinoatrial disorder (i.e. Sick Sinus Syndrome) digoxin may cause or exacerbate sinus bradycardia or cause sinoatrial block.</p><p><u>Myocardial infarction</u></p><p>The administration of digoxin in the period immediately following myocardial infarction is not contraindicated. However, the use of inotropic drugs in some patients in this setting may result in undesirable increases in myocardial oxygen demand and ischaemia, and some retrospective follow-up studies have suggested digoxin to be associated with an increased risk of death. The possibility of arrhythmias arising in patients who may be hypokalaemic after myocardial infarction and are likely to be haemodynamically unstable must be borne in mind. The limitations imposed thereafter on direct current cardioversion must also be remembered.</p><p><u>Cardiac amyloidosis</u></p><p>Treatment with digoxin should generally be avoided in patients with heart failure associated with cardiac amyloidosis. However, if alternative treatments are not appropriate, digoxin can be used to control the ventricular rate in patients with cardiac amyloidosis and atrial fibrillation.</p><p><u>Myocarditis</u></p><p>Digoxin can rarely precipitate vasoconstriction and therefore should be avoided in patients with myocarditis.</p><p><u>Beri-beri heart disease</u></p><p>Patients with beri-beri heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly.</p><p><u>Constrictive pericarditis</u></p><p>Digoxin should not be used in constrictive pericarditis unless it is used to control the ventricular rate in atrial fibrillation or to improve systolic dysfunction.</p><p><u>Exercise tolerance</u></p><p>Digoxin improves exercise tolerance in patients with impaired left ventricular systolic dysfunction and normal sinus rhythm. This may or may not be associated with an improved haemodynamic profile. However, the benefit of digoxin in patients with supraventricular arrhythmias is most evident at rest, less evident with exercise.</p><p><u>Withdrawal</u></p><p>In patients receiving diuretics and an ACE inhibitor, or diuretics alone, the withdrawal of digoxin has been shown to result in clinical deterioration.</p><p><u>Electrocardiograhy</u></p><p>The use of therapeutic doses of digoxin may cause prolongation of the PR interval and depression of the ST segment on the electrocardiogram.</p><p>Digoxin may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects reflect an expected effect of the drug and are not indicative of toxicity.</p><p><u>Severe respiratory disease</u></p><p>Patients with severe respiratory disease may have an increased myocardial sensitivity to digitalis glycosides.</p><p><u>Hypokalaemia</u></p><p>Hypokalaemia sensitises the myocardium to the actions of cardiac glycosides.</p><p><u>Hypoxia, hypomagnesaemia and hypercalcaemia</u></p><p>Hypoxia, hypomagnesaemia and marked hypercalcaemia increase myocardial sensitivity to cardiac glycosides.</p><p><u>Thyroid disease</u></p><p>Administering digoxin to a patient with thyroid disease requires care. Initial and maintenance doses of digoxin should be reduced when thyroid function is subnormal. In hyperthyroidism there is relative digoxin resistance and the dose may have to be increased. During the course of treatment of thyrotoxicosis, dosage should be reduced as the thyrotoxicosis comes under control.</p><p><u>Malabsorption</u></p><p>Patients with malabsorption syndrome or gastro-intestinal reconstructions may require larger doses of digoxin.</p><p><u>Chronic congestive cardiac failure</u></p><p>Although many patients with chronic congestive cardiac failure benefit from acute administration of digoxin, there are some in whom it does not lead to constant, marked or lasting haemodynamic improvement. It is therefore important to evaluate the response of each patient individually when digoxin is continued long-term.</p><p><u>Direct current cardioversion:</u></p><p>The risk of provoking dangerous arrhythmias with direct current cardioversion is greatly increased in the presence of digitalis toxicity and is in proportion to the cardioversion energy used.</p><p>For elective direct current cardioversion of a patient who is taking digoxin, the drug should be withheld for 24 h before cardioversion is performed. In emergencies, such as cardiac arrest when attempting cardioversion the lowest effective energy should be applied.</p><p>Direct current cardioversion is inappropriate in the treatment of arrhythmias thought to be caused by cardiac glycosides.</p><p><u>Digoxin tablets contain lactose.</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>These may arise from effects on the renal excretion, tissue binding, plasma protein binding, distribution within the body, gut absorptive capacity, P-glycoprotein activity and sensitivity to digoxin. Consideration of the possibility of an interaction whenever concomitant therapy is contemplated is the best precaution and a check on serum digoxin concentration is recommended when any doubt exists.</p><p>Digoxin is a substrate of P-glycoprotein. Thus, inhibitors of P-glycoprotein may increase blood concentrations of digoxin by enhancing its absorption and/or by reducing its renal clearance (see Section 5.2). Induction of P-glycoprotein can result in decreases in plasma concentrations of digoxin.</p><p><u>Combinations that should be avoided</u></p><p><em>Combinations which can increase effects of digoxin when co-administered:</em></p><p>Digoxin, in association with beta-adrenoceptor blocking drugs, may increase atrio-ventricular conduction time.</p><p>Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to digoxin; they include lithium salts, corticosteroids, carbenoxolone and some diuretics. Co- administration with diuretics such as loop or hydrochlorothiazide should be under close monitoring of serum electrolytes and renal function.</p><p>Calcium, particularly if administered rapidly by the I.V. route, may produce serious arrhythmias in digitalised patients.</p><p>Sympathomimetic drugs have direct positive chronotropic effects that can promote cardiac arrhythmias and may also lead to hypokalaemia, which can lead to or worsen cardiac arrhythmias. Concomitant use of digoxin and sympathomimetics may increase the risk of cardiac arrhythmias.</p><p><u>Combinations requiring caution</u></p><p>Patient should consult a healthcare professional prior to use Senna if taking cardiac medications such as cardiac glycosides (digoxin) or antiarrhythmic medications which may aggravate electrolytic imbalance.&nbsp;</p><p>Patient should consult a healthcare professional prior to use Panax ginseng if taking digoxin due to ginseng effect on serum digoxin measurement and binding of digoxin like immunereactive components of ginseng with Fab Fragment of anti-digoxin antibody (Digiband).</p><p><em>Combinations which can increase the effects of digoxin when co-administered:</em></p><p>amiodarone, canagliflozin, daclatasvir, flibanserin, flecainide, prazosin, propafenone, quinidine, spironolactone, macrolide antibiotics e.g. erythromycin and clarythromycin, tetracycline (and possibly other antibiotics), gentamicin, isavuconazole, itraconazole, ivacaftor, quinine, trimethoprim, alprazolam, indomethacin, propantheline, mirabegron, nefazodone, atorvastatin, ciclosporine, epoprostenol (transient), vasopressin receptor antagonists (tolvaptan and conivaptan), carvedilol, ritonavir/ritonavir containing regimens, taleprevir, dronedarone, ranolazine, simeprevir, telmisartan, lapatinib, ticagrelor, vandetanib, velpatasvir, venetoclax and vemurafenib. Care should be taken when any of the above medicinal products are used in combination with digoxin. Serum digoxin concentrations should be monitored and used for titration of digoxin.</p><p>The concomitant use of digoxin and sennosides may be associated with a moderate increase in the risk of digoxin toxicity in heart failure patients.</p><p>Patients receiving digoxin are more susceptible to the effects of suxamethonium-exacerbated hyperkalaemia.</p><p>Co-administration of lapatinib with orally administered digoxin resulted in an increase in the AUC of digoxin. Caution should be exercised when dosing digoxin concurrently with lapatinib.</p><p>Drugs that modify afferent and efferent arteriole vascular tone may alter glomerular filtration. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) decrease angiotensin II-mediated efferent arteriole vasoconstriction, while non-steroidal anti- inflammatory drugs (NSAIDs) and cyclooxygenase-2 enzyme (COX-2) inhibitors decrease prostaglandin-mediated afferent arteriole vasodilation. ARBs, ACEIs, NSAIDs, and COX-2 inhibitors did not significantly alter digoxin pharmacokinetics or did not alter PK parameters in a consistent manner. However, these drugs may modify renal function in some patients, resulting in a secondary increase in digoxin.</p><p>Calcium channel blocking agents may either increase or cause no change in serum digoxin levels. Verapamil, felodipine and tiapamil increase serum digoxin levels. Nifedipine and diltiazem may increase or have no effect on serum digoxin levels while isradipine causes no change. Calcium channel blockers are also known to have depressant effects on sinoatrial and atrioventricular nodal conduction, particularly diltiazem and verapamil.</p><p>Proton pump inhibitors (PPI) are able to increase plasma levels of digoxin by inhibiting its efflux. Metabolism of digoxin in the gastrointestinal tract is inhibited by omeprazole, resulting in increased plasma levels of digoxin. Similar effects have been reported with pantoprazole and rabeprazole to a lesser extent.</p><p><em>Combinations which can decrease the effects of digoxin when co-administered:</em></p><p>antacids, some bulk laxatives, kaolin-pectin, acarbose, neomycin, penicillamine, rifampicin, some cytostatics, metoclopramide, sulfasalazine, adrenaline, salbutamol, cholestyramine, phenytoin, St John&rsquo;s wort (Hypericum perforatum), bupropion and supplemental enteral nutrition.</p><p>Bupropion and its major circulating metabolite, with and without digoxin, stimulated OATP4C1- mediated digoxin transport. Digoxin has been identified as a substrate for aOATP4C1 in the basolateral side of the proximal renal tubules. Binding of bupropion and its metabolites to OATP4C1 could possibly increase the transport of digoxin and therefore, increase the renal secretion of digoxin.</p><p><u>Other interactions</u></p><p>Milrinone does not alter steady-state serum digoxin levels.</p><p><strong>P-Glycoprotein (PGP) Inducers/Inhibitors<sup>1</sup></strong></p><p>Digoxin is a substrate of P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary &ndash;intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics.</p><p><strong>Pharmacokinetic Drug Interactions<sup>1</sup></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Digoxin concentrations increased greater than 50%</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Digoxin Serum Concentration Increase</p></td><td style="vertical-align:top; width:268px"><p>Digoxin AUC Increase</p></td><td style="vertical-align:top; width:978px"><p>Recommendations</p></td></tr><tr><td style="vertical-align:top"><p>Amiodarone</p></td><td style="vertical-align:top"><p>70%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td><td rowspan="15" style="vertical-align:top; width:978px"><p>Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing dose by approximately 30-50% or by modifying the dosing frequency and continue monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Captopril</p></td><td style="vertical-align:top"><p>58%</p></td><td style="vertical-align:top; width:268px"><p>39%</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>70%</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>150%</p></td></tr><tr><td style="vertical-align:top"><p>Gentamicin</p></td><td style="vertical-align:top"><p>129-212%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole</p></td><td style="vertical-align:top"><p>80%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Lapatinib</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>180%</p></td></tr><tr><td style="vertical-align:top"><p>Propafenone</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>60-270%</p></td></tr><tr><td style="vertical-align:top"><p>Quinidine</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Ranolazine</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>86%</p></td></tr><tr><td style="vertical-align:top"><p>Telaprevir</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top; width:268px"><p>85%</p></td></tr><tr><td style="vertical-align:top"><p>Tetracycline</p></td><td style="vertical-align:top"><p>100%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Verapamil</p></td><td style="vertical-align:top"><p>50-75%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Digoxin concentrations increased less than 50%</p></td></tr><tr><td style="vertical-align:top"><p>Carvedilol</p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top; width:268px"><p>14%</p></td><td rowspan="15" style="vertical-align:top; width:978px"><p>Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring</p></td></tr><tr><td style="vertical-align:top"><p>Conivaptan</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top; width:268px"><p>43%</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Indomethacin</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Nefazodone</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top; width:268px"><p>15%</p></td></tr><tr><td style="vertical-align:top"><p>Nifedipine</p></td><td style="vertical-align:top"><p>45%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Propantheline</p></td><td style="vertical-align:top"><p>24%</p></td><td style="vertical-align:top; width:268px"><p>24%</p></td></tr><tr><td style="vertical-align:top"><p>Quinine</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top; width:268px"><p>33%</p></td></tr><tr><td style="vertical-align:top"><p>Rabeprazole</p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top; width:268px"><p>19%</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir</p></td><td style="vertical-align:top"><p>27%</p></td><td style="vertical-align:top; width:268px"><p>49%</p></td></tr><tr><td style="vertical-align:top"><p>Spironolactone</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Telmisartan</p></td><td style="vertical-align:top"><p>20-49%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr><tr><td style="vertical-align:top"><p>Ticagrelor</p></td><td style="vertical-align:top"><p>31%</p></td><td style="vertical-align:top; width:268px"><p>28%</p></td></tr><tr><td style="vertical-align:top"><p>Tolvaptan</p></td><td style="vertical-align:top"><p>30%</p></td><td style="vertical-align:top; width:268px"><p>20%</p></td></tr><tr><td style="vertical-align:top"><p>Trimethoprim</p></td><td style="vertical-align:top"><p>22-28%</p></td><td style="vertical-align:top; width:268px"><p>NA</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Digoxin concentrations decreased</p></td></tr><tr><td style="vertical-align:top; width:576px"><p>Acarbose, activated charcoal, albuterol, antacids, certain cancer chemotherapy or radiation therapy, cholestyramine, colestipol, extenatide, kaolin-pectin, meals high in bran, metoclopramide, miglitol, neomycin, penicillamine, phenytoin, rifampin, St. John&rsquo;s Wort, sucralfate and sulfasalazine</p></td><td style="vertical-align:top; width:991px"><p>Measure serum digoxin concentrations before initiating concomitant drugs. Continue monitoring and increase digoxin dose by approximately 20-40% as necessary.</p></td></tr></tbody></table><p>NA = Not available/reported</p><p><strong>Potentially Significant Pharmacodynamic Drug Interactions<sup>1</sup></strong></p><p>Because of considerable variability of pharmacodynamic interactions, the dosage of digoxin should be individualized when patients receive these medications concurrently.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Drugs that Affect Renal Function</p></td><td colspan="2" style="vertical-align:top"><p>A decline in GFR or tubular secretion, as from ACE inhibitors, angiotensin receptor blockers, nonsteroidal anti-inflammatory drugs [NSAIDS], COX-2 inhibitors may impair the excretion of digoxin.</p></td></tr><tr><td style="vertical-align:top"><p>Antiarrthymics</p></td><td style="vertical-align:top"><p>Dofetilide</p></td><td style="vertical-align:top"><p>Concomitant administration with digoxin was associated with a higher rate of torsades de pointes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sotalol</p></td><td style="vertical-align:top"><p>Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dronedarone</p></td><td style="vertical-align:top"><p>Sudden death was more common in patients receiving digoxin with dronedarone than on either alone; it is not clear whether this represents an interaction or is related to the presence of advanced heart disease, a known risk factor for sudden death in patients receiving digoxin.</p></td></tr><tr><td style="vertical-align:top"><p>Parathyroid Hormone Analog</p></td><td style="vertical-align:top"><p>Teriparatide</p></td><td style="vertical-align:top"><p>Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. Teriparatide transiently increases serum calcium.</p></td></tr><tr><td style="vertical-align:top"><p>Thyroid supplement</p></td><td style="vertical-align:top"><p>Thyroid</p></td><td style="vertical-align:top"><p>Treatment of hypothyroidism in patients taking digoxin may increase the dose requirements of digoxin.</p></td></tr><tr><td style="vertical-align:top"><p>Sympathomimetics</p></td><td style="vertical-align:top"><p>Epinephrine Norepinephrine Dopamine</p></td><td style="vertical-align:top"><p>Can increase the risk of cardiac arrhythmias</p></td></tr><tr><td style="vertical-align:top"><p>Neuromuscular Blocking Agents</p></td><td style="vertical-align:top"><p>Succinylcholine</p></td><td style="vertical-align:top"><p>May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin.</p></td></tr><tr><td style="vertical-align:top"><p>Supplements</p></td><td style="vertical-align:top"><p>Calcium</p></td><td style="vertical-align:top"><p>If administered rapidly by intravenous route, can produce serious arrhythmias in digitalized patients.</p></td></tr><tr><td style="vertical-align:top"><p>Beta-adrenergic blockers and calcium channel blockers</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Additive effects on AV node conduction can result in bradycardia and advanced or complete heart block</p></td></tr><tr><td style="vertical-align:top"><p>Hyperpolarization-activated cyclic nucleotide-gated channel blocker</p></td><td style="vertical-align:top"><p>Ivabradine</p></td><td style="vertical-align:top"><p>Can increase the risk of bradycardia.</p></td></tr></tbody></table><p><strong>Effect of other drugs on digoxin</strong></p><p>Concomitant administration of MYCAPSSA (OCTEROTIDE) with digoxin resulted in a decrease in digoxin peak exposure.<sup>2</sup></p><p>Treatment with Gilenya (FINGOLIMOD) should not be initiated in patients receiving substances, which may decrease heart rate, such as digoxin because of the potential additive effects on heart rate.<sup>3</sup></p><p><strong>Drug/Laboratory Test Interactions<sup>1</sup></strong></p><p>Endogenous substances of unknown composition (digoxin-like immunoreactive substances [DLIS]) can interfere with standard radioimmunoassays for digoxin. The interference most often causes results to be falsely positive or falsely elevated, but sometimes it causes results to be falsely reduced. Some assays are more subject to these failings than others. Several LC/MS/MS methods are available that may provide less susceptibility to DLIS interference. DLIS are present in up to half of all neonates and in varying percentages of pregnant women, patients with hypertrophic cardiomyopathy, patients with renal or hepatic dysfunction, and other patients who are volume-expanded for any reason. The measured levels of DLIS (as digoxin equivalents) are usually low (0.2-0.4 ng/mL), but sometimes they reach levels that would be considered therapeutic or even toxic. In some assays, spironolactone, canrenone, and potassium canrenoate may be falsely detected as digoxin, at levels up to 0.5 ng/mL. Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen can cause similar interference.</p><p>Spironolactone and DLIS are much more extensively protein-bound than digoxin. As a result, assays of free digoxin levels in protein-free ultrafiltrate (which tend to be about 25% less than total levels, consistent with the usual extent of protein binding) are less affected by spironolactone or DLIS. It should be noted that ultrafiltration does not solve all interference problems with alternative medicines. The use of an LC/MS/MS method may be the better option according to the good results it provides, especially in terms of specificity and limit of quantization.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The use of digoxin in pregnancy is not contraindicated, although the dosage may be less predictable in pregnant than in non-pregnant women, with some requiring an increased dosage of digoxin during pregnancy. As with all drugs, use should be considered only when the expected clinical benefit of treatment to the mother outweighs any possible risk to the developing foetus.</p><p>Despite extensive antenatal exposure to digitalis preparations, no significant adverse effects have been observed in the foetus or neonate when maternal serum digoxin concentrations are maintained within the normal range. Although it has been speculated that a direct effect of digoxin on the myometrium may result in relative prematurity and low birthweight, a contributing role of the underlying cardiac disease cannot be excluded. Maternally-administered digoxin has been successfully used to treat foetal tachycardia and congestive heart failure.</p><p>Adverse foetal effects have been reported in mothers with digitalis toxicity.</p><p><u>Breast-feeding</u></p><p>Although digoxin is excreted in breast milk, the quantities are minute and breast feeding is not contraindicated.</p><p><u>Fertility</u></p><p>There is no information available on the effect of digoxin on human fertility. No data are available on whether or not digoxin has teratogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since central nervous system and visual disturbances have been reported in patients receiving digoxin, patients should exercise caution before driving, using machinery or participating in dangerous activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect.</p><p>Hence, adverse reactions are less common when digoxin is used within the recommended dose range or therapeutic serum concentration range and when there is careful attention to concurrent medications and conditions.</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as:</p><p>Very common &ge; 1/10</p><p>Common &ge; 1/100 and &lt; 1/10</p><p>Uncommon &ge; 1/1000 and &lt; 1/100</p><p>Rare &ge; 1/10,000 and &lt; 1/1000</p><p>Very rare &lt; 1/10,000, including isolated reports.</p><p>Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Adverse drug reactions identified through post- marketing surveillance were considered to be rare or very rare (including isolated reports).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Side effects</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Thrombocytopaenia</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition</p><p>disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Psychotic disorder, apathy, confusional state</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nervous system disorder, dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Visual impairment (blurred vision or xanthopsia)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arrhythmia, conduction disorder, bigeminy, trigeminy, PR prolongation, sinus bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Supraventricular tachyarrhythmia, atrial tachycardia (with or without block), supraventricular tachycardia (nodal arrythymia), ventricular arrhythmia, ventricular extrasystoles,</p><p>electrocardiaogram ST segment depression</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Intestinal ischaemia, gastrointestinal necrosis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash*</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Gynaecomastia*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Fatigue, malaise, asthenia</p></td></tr></tbody></table><p>* See &ldquo;Description of selected adverse reactions&rdquo; <u>Description of selected adverse reactions</u></p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Skin rashes of urticarial or scarlatiniform character may be accompanied by pronounced eosinophilia.</p><p><em>Reproductive system and breast disorders</em></p><p>Gynaecomastia can occur with long term administration.</p><p><strong><u>To reports any side effect(s):</u></strong></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><u>Please report adverse drug events to: </u></p><ul><li>The National Pharmacovigilance Centre (NPC):</li><li>&nbsp;Fax: +966-11-205-7662</li><li>SFDA Call Center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>&nbsp;Website: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p><strong>- Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:496px"><tbody><tr><td style="vertical-align:top; width:493px"><p>-&nbsp; Please contact the relevant competent authority.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p>The symptoms and signs of toxicity are generally similar to those described in Section 4.8, but may be more frequent and can be more severe.</p><p>Signs and symptoms of digoxin toxicity become more frequent with levels above 2.0 nanograms/ml (2.56 nanomol/l) although there is considerable inter-individual variation. However, in deciding whether a patient&#39;s symptoms are due to digoxin, the clinical state, together with serum electrolyte levels and thyroid function are important factors (see Section 4.2). In patients undergoing haemodialysis, digoxin use is associated with increased mortality; patients with low pre-dialysis potassium concentrations are most at risk.</p><p><u>Adults</u></p><p>In adults without heart disease, clinical observation suggests that an overdose of digoxin of 10 to 15 mg was the dose resulting in death of half of the patients. If more than 25 mg of digoxin was ingested by an adult without heart disease, death or progressive toxicity responsive only to digoxin-binding Fab antibody fragments resulted.</p><p><em>Cardiac manifestations</em></p><p>Cardiac manifestations are the most frequent and serious sign of both acute and chronic toxicity. Peak cardiac effects generally occur 3 to 6 hours following overdose and may persist for the ensuing 24 hours or longer. Digoxin toxicity may result in almost any type of arrhythmia. Multiple rhythm disturbances in the same patient are common. These include paroxysmal atrial tachycardia with variable atrioventricular (AV) block, accelerated junctional rhythm, slow atrial fibrillation (with very little variation in the ventricular rate) and bi directional ventricular tachycardia.</p><p>Premature ventricular contractions (PVCs) are often the earliest and most common arrhythmia. Bigeminy or trigeminy also occur frequently.</p><p>Sinus bradycardia and other bradyarrhythmias are very common.</p><p>First, second, third degree heart blocks and AV dissociation are also common.</p><p>Early toxicity may only be manifested by prolongation of the PR interval.</p><p>Ventricular tachycardia may also be a manifestation of toxicity.</p><p>Cardiac arrest from asystole or ventricular fibrillation due to digoxin toxicity is usually fatal.</p><p>Acute massive digoxin overdose can result in mild to pronounced hyperkalaemia due to inhibition of the sodium-potassium (Na<sup>+</sup>-K<sup>+</sup>) pump. Hypokalaemia may contribute to toxicity (see Section 4.4).</p><p><em>Non-cardiac manifestations</em></p><p>Gastrointestinal symptoms are very common in both acute and chronic toxicity. The symptoms precede cardiac manifestations in approximately half of the patients in most literature reports. Anorexia, nausea and vomiting have been reported with an incidence up to 80 %. These symptoms usually present early in the course of an overdose.</p><p>Neurologic and visual manifestations occur in both acute and chronic toxicity. Dizziness, various CNS disturbances, fatigue and malaise are very common. The most frequent visual disturbance is an aberration of colour vision (predominance of yellow green). These neurological and visual symptoms may persist even after other signs of toxicity have resolved.</p><p>In chronic toxicity, non-specific non-cardiac symptoms, such as malaise and weakness, may predominate.</p><p><u>Paediatric population</u></p><p>In children aged 1 to 3 years without heart disease, clinical observation suggests that an overdose of digoxin of 6 to 10 mg was the dose resulting in death in half of the patients.</p><p>If more than 10 mg of digoxin was ingested by a child aged 1 to 3 years without heart disease, the outcome was uniformly fatal when Fab fragment treatment was not given.</p><p>Most manifestations of chronic toxicity in children occur during or shortly after digoxin overdose.</p><p><em>Cardiac manifestations</em></p><p>The same arrhythmias or combination of arrhythmias that occur in adults can occur in paediatrics. Sinus tachycardia, supraventricular tachycardia, and rapid atrial fibrillation are seen less frequently in the paediatric population.</p><p>Paediatric patients are more likely to present with an AV conduction disturbance or a sinus bradycardia.</p><p>Ventricular ectopy is less common, however in massive overdose, ventricular ectopy, ventricular tachycardia and ventricular fibrillation have been reported.</p><p>In neonates, sinus bradycardia or sinus arrest and/or prolonged PR intervals are frequent signs of toxicity. Sinus bradycardia is common in young infants and children. In older children, AV blocks are the most common conduction disorders.</p><p>Any arrhythmia or alteration in cardiac conduction that develops in a child taking digoxin should be assumed to be caused by digoxin, until further evaluation proves otherwise.</p><p><em>Non-cardiac manifestations</em></p><p>The frequent non-cardiac manifestations are similar to those seen in adults are gastrointestinal, CNS and visual. However, nausea and vomiting are not frequent in infants and small children.</p><p>In addition to the undesirable effects seen with recommended doses, weight loss in older age groups and failure to thrive in infants, abdominal pain due to mesenteric artery ischaemia, drowsiness and behavioural disturbances including psychotic manifestations have been reported in overdose</p><p><u>Treatment</u></p><p>After recent ingestion, such as accidental or deliberate self-poisoning, the load available for absorption may be reduced by gastric lavage. Gastric lavage increases vagal tone and may precipitate or worsen arrhythmias. Consider pre-treatment with atropine if gastric lavage is performed. Treatment with digitalis Fab antibody usually renders gastric lavage unnecessary. In the rare instances in which gastric lavage is indicated, it should only be performed by individuals with proper training and expertise.</p><p>Patients with massive digitalis ingestion should receive large doses of activated charcoal to prevent absorption and bind digoxin in the gut during enteroenteric recirculation.</p><p>If hypokalaemia is present, it should be corrected with potassium supplements either orally or intravenously, depending on the urgency of the situation. In cases where a large amount of digoxin has been ingested hyperkalaemia may be present due to release of potassium from skeletal muscle. Before administering potassium in digoxin overdose the serum potassium level must be known.</p><p>Bradyarrhythmias may respond to atropine but temporary cardiac pacing may be required. Ventricular arrhythmias may respond to lignocaine or phenytoin.</p><p>Dialysis is not particularly effective in removing digoxin from the body in potentially life-threatening toxicity.</p><p>Digoxin-specific antibody Fab is a specific treatment for digoxin toxicity and is very effective. Rapid reversal of the complications that are associated with serious poisoning by digoxin, digitoxin and related glycosides has followed I.V. administration of digoxin-specific (ovine) antibody fragments (Fab). For details, consult the literature supplied with antibody fragments.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cardiac therapy, cardiac glycosides, digitalis glycosides.</p><p>ATC code: C01AA05</p><p><u>Mechanism of action</u></p><p>Digoxin increases contractility of the myocardium by direct activity. This effect is proportional to dose in the lower range and some effect is achieved with quite low dosing; it occurs even in normal myocardium although it is then entirely without physiological benefit. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na<sup>+</sup>-K<sup>+</sup>) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect.</p><p>Digoxin exerts the same fundamental effect of inhibition of the Na<sup>+</sup>-K<sup>+</sup> exchange mechanism on cells of the autonomic nervous system, stimulating them to exert indirect cardiac activity. Increases in efferent vagal impulses result in reduced sympathetic tone and diminished impulse conduction rate through the atria and atrio-ventricular node. Thus, the major beneficial effect of digoxin is reduction of ventricular rate.</p><p>Intravenous administration of a loading dose produces an appreciable pharmacological effect within 5 to 30 mins, while using the oral route the onset of effect occurs in 0.5 to 2 hours.</p><p><u>Pharmacodynamic effects</u></p><p>The PROVED trial designed to determine the effectiveness of digoxin in 88 patients with chronic, stable mild to moderate heart failure. Withdrawal of digoxin or its continuation was performed in a prospective, randomised, double-blind, placebo-controlled multicentre trial of patients with chronic, stable mild to moderate heart failure secondary to left ventricular systolic dysfunction who had normal sinus rhythm and were receiving long-term treatment with diuretic drugs and digoxin. Patients withdrawn from digoxin therapy showed worsened maximal exercise capacity (p = 0.003) an increased incidence of treatment failures (p = 0.039) and a decreased time to treatment failure (p = 0.037). Patients who continued to receive digoxin had a lower body weight (p = 0.044) and heart rate (p = 0.003) and a higher left ventricular ejection fraction (p = 0.016). The overall percentage of participants having one or more adverse event was similar in the two groups: 59 % in the placebo group and 69 % in the digoxin group. The types of adverse event were unspecified</p><p>The RADIANCE trial examined the effects of discontinuation of digoxin in stable NYHA class II and III patients who were receiving diuretics and ACE inhibitors. The 178 patients were initially stabilised on a combination of captopril or enalapril, diuretics and digoxin, then randomised to continue digoxin</p><p>therapy or change to placebo. The relative risk of worsening disease in the placebo group was 5.9 compared to the digoxin group. Withdrawal of digoxin was accompanied by worsening symptoms, reduced exercise tolerance, and a deteriorating quality of life, indicating that patients with CHF were at considerable risk from discontinuation of the drug in spite of the continuation of therapy with diuretics and ACE inhibitors. Approximately 56 % in the placebo group and 49% in the digoxin group experienced unspecified side effects.</p><p>In the DIG trial, 6800 patients with heart failure were randomised to receive digoxin or placebo. No difference was found in all-cause mortality between patients who were treated with digoxin and those who were given placebo. In the digoxin group, there was a trend toward a decrease in the risk of death attributed to worsening heart failure (risk ratio, 0.88; 95% confidence interval, 0.77 to 1.01; p = 0.06). However, the patients who received digoxin had significantly (p&lt;0.001) fewer hospital admissions when the drug was given in addition to diuretics and ACE inhibitors. Digoxin therapy was most beneficial in patients with ejection fractions of &le;25%, patients with enlarged hearts (cardiothoracic ratio of &gt;0.55), and patients in NYHA functional class III or IV. In the DIG study, 11.9 % of patients in the digoxin arm and 7.9 % of patients in the placebo arm were suspected of having digoxin toxicity, the most common symptoms being new episodes of ventricular fibrillation, supraventricular arrhythmia, tachycardia, or advanced atrioventricular block.</p><p>The AFFIRM study involved a total of 4060 patients recruited to a randomised, multicentre comparison of two treatment strategies in patients with atrial fibrillation and a high risk of stroke or death. The primary end point was overall mortality. There were 356 deaths among the patients assigned to rhythm-control therapy (amiodarone, disopyramide, flecainide, moricizine, procainamide, propafenone, quinidine, sotalol, and combinations of these drugs) and 310 deaths among those assigned to rate-control [&beta;-blockers, calcium-channel blockers (verapamil and diltiazem), digoxin, and combinations of these drugs) therapy (mortality at five years, 23.8% and 21.3%, respectively; hazard ratio, 1.15 [95% confidence interval, 0.99 to 1.34]; p=0.08). More patients in the rhythm-control group than in the rate-control group were hospitalised, and there were more adverse drug effects in the rhythm-control group as well.</p><p>Indirect cardiac contractility changes also result from changes in venous compliance brought about by the altered autonomic activity and by direct venous stimulation. The interplay between direct and indirect activity governs the total circulatory response, which is not identical for all subjects. In the presence of certain supraventricular arrhythmias, the neurogenically mediated slowing of AV conduction is paramount.</p><p>The degree of neurohormonal activation occurring in patients with heart failure is associated with clinical deterioration and an increased risk of death. Digoxin reduces activation of both the sympathetic nervous system and the (renin-angiotensin) system independently of its inotropic actions, and may thus favourably influence survival. Whether this is achieved via direct sympathoinhibitory effects or by re-sensitising baroreflex mechanisms remains unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The T<sub>max</sub> following IV administration is approximately 1 to 5 hours, while the T<sub>max</sub> for oral administration is 2 to 6 hours. Upon oral administration, digoxin is absorbed from the stomach and upper part of the small intestine. When digoxin is taken after meals, the rate of absorption is slowed, but the total amount of digoxin absorbed is usually unchanged. When taken with meals high in fibre, however, the amount absorbed from an oral dose may be reduced.</p><p>The bioavailability of orally administered digoxin is approximately 63 % in tablet form and 75 % as oral solution.</p><p><u>Distribution</u></p><p>The initial distribution of digoxin from the central to the peripheral compartment generally lasts from 6 to 8 h. This is followed by a more gradual decline in serum digoxin concentration, which is dependent upon digoxin elimination from the body. The volume of distribution is large (Vdss = 510 litres in healthy volunteers), indicating digoxin to be extensively bound to body tissues. The highest digoxin concentrations are seen in the heart, liver and kidney, that in the heart averaging 30-fold that in the systemic circulation. Although the concentration in skeletal muscle is far lower, this store cannot be overlooked since skeletal muscle represents 40 % of total body weight. Of the small proportion of digoxin circulating in plasma, approximately 25 % is bound to protein.</p><p><u>Biotransformation</u></p><p>The majority of digoxin is excreted by the kidneys as an intact drug, although a small fraction of the dose is metabolised to pharmacologically active and inactive metabolites. The main metabolites of digoxin are dihydrodigoxin and digoxygenin.</p><p><u>Elimination</u></p><p>The major route of elimination is renal excretion of the unchanged drug.</p><p>Digoxin is a substrate for P-glycoprotein. As an efflux protein on the apical membrane of enterocytes, P-glycoprotein may limit the absorption of digoxin. P-glycoprotein in renal proximal tubules appears to be an important factor in the renal elimination of digoxin (see Section 4.5).</p><p>Following I.V. administration to healthy volunteers, between 60 and 75 % of a digoxin dose is recovered unchanged in the urine over a six day follow-up period. Total body clearance of digoxin has been shown to be directly related to renal function, and percent daily loss is thus a function of creatinine clearance. The total and renal clearances of digoxin have been found to be 193 &plusmn; 25 ml/min and 152 &plusmn; 24 ml/min in a healthy control population.</p><p>In a small percentage of individuals, orally administered digoxin is converted to cardioinactive reduction products (digoxin reduction products or DRPs) by colonic bacteria in the gastrointestinal tract. In these subjects over 40 % of the dose may be excreted as DRPs in the urine. Renal clearances of the two main metabolites, dihydrodigoxin and digoxygenin, have been found to be 79 &plusmn; 13 ml/min and 100 &plusmn; 26 ml/min, respectively.</p><p>In the majority of cases however, the major route of digoxin elimination is renal excretion of the unchanged drug.</p><p>The terminal elimination half-life of digoxin in patients with normal renal function is 30 to 40 h.</p><p>Since most of the drug is bound to the tissues rather than circulating in the blood, digoxin is not effectively removed from the body during cardiopulmonary by-pass. Furthermore, only about 3 % of a digoxin dose is removed from the body during 5 h of haemodialysis.</p><p><u>Special patient populations</u></p><p><em>Paediatric population</em></p><p>In the newborn period, renal clearance of digoxin is diminished and suitable dosage adjustments must be observed. This is especially pronounced in the premature infant since renal clearance reflects maturation of renal function. Digoxin clearance has been found to be 65.6 &plusmn; 30 ml/min/1.73m<sup>2 </sup>at three months, compared to only 32 &plusmn; 7 ml/min/1.73m<sup>2</sup> at one week. By 12 months digoxin clearance of 88 &plusmn; 43 ml / min / 1.73m<sup>2</sup> has been reported. Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight and body surface area.</p><p><em>Renal impairment</em></p><p>The terminal elimination half-life of digoxin is prolonged in patients with impaired renal function, and in anuric patients may be of the order of 100 h.</p><p><em>Hepatic impairment</em></p><p>Hepatic impairment has little effect on digoxin clearance.</p><p><em>Elderly</em></p><p>Age-related declines in renal function in elderly patients can result in a lower rates of digoxin clearance than in younger subjects, with reported digoxin clearance rates in the elderly of 53 ml/min/1.73m<sup>2</sup>.</p><p><em>Gender</em></p><p>Digoxin clearance is 12% &ndash; 14% less in females than males and may need to be considered in dosing calculations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, mutagenesis</u></p><p>Digoxin showed no genotoxic potential in in vitro studies (Ames test and mouse lymphoma). No data are available on the carcinogenic potential of digoxin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ph. Eur.</p><p>Maize Starch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ph. Eur.</p><p>Modified Maize Starch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;USP</p><p>Rice Starch&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Ph. Eur.</p><p>Magnesium Stearate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ph. Eur.</p><p>Purified Water&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ph. Eur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amber glass bottle:	60 months
Blister packs:	        60 months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25<sup>o</sup>C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottle with low-density polyethylene snap-fit closure</p><p>Pack sizes: 28, 50, 500 tablets</p><p>Amber glass bottle with a clic-loc child resistant closure</p><p>Pack size: 56 tablets</p><p>White opaque PVC/aluminium foil blister</p><p>Pack sizes: 30, 60, 90, 100, 120 tablets</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited 3016
Lake Drive,
Citywest Business Campus, Dublin 24,
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>